Cingulate (CING) vs Fortress Biotech (FBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed Fortress Biotech (FBIO) over the past year, gaining 27.8% versus a loss of 26.6%. Cingulate is the larger company by market cap ($67.5 million vs $64.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | FBIO |
|---|---|---|
| Share price | $4.51 | $1.90 |
| Market cap | $67.48M | $64.11M |
| 1-day change | -14.26% | +7.34% |
| YTD return | +3.92% | -48.09% |
| 1-year return | +27.76% | -26.64% |
| 5-year return | — | -95.52% |
| P/E ratio (TTM) | — | 0.83 |
| EPS (TTM) | $-2.67 | $2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $63.26M |
| Revenue growth (YoY) | — | +9.69% |
| Net income (latest FY) | $-22.45M | $6.82M |
| Gross margin | — | 66.92% |
| Operating margin | — | -111.00% |
| Net margin | — | 10.77% |
| 52-week high | $11.89 | $4.53 |
| 52-week low | $3.16 | $1.64 |
| Distance from 52-week high | -62.07% | -58.06% |
| Analyst consensus | none | none |
| Avg. price target upside | +370.07% | +163.16% |
| Average volume | 178.82K | 281.49K |
| Shares outstanding | 14.96M | 33.74M |
| Employees | 14 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed FBIO by 54.4 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
CING vs FBIO FAQ
Which is bigger, Cingulate or Fortress Biotech?
Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $64.11M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, CING or FBIO?
CING returned +27.76% over the past 12 months, compared with -26.64% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Fortress Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.